4.6 Article

Vascular cognitive impairment

Journal

NATURE REVIEWS DISEASE PRIMERS
Volume 4, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/nrdp.2018.3

Keywords

-

Funding

  1. Boehringer Ingelheim
  2. Biogen MA Inc
  3. Piramal Neuroimaging
  4. Roche BV
  5. Janssen Stellar
  6. Combinostics
  7. Takeda
  8. Navidea Biopharmaceuticals
  9. Michael J. Fox Foundation
  10. Moleac
  11. Nutricia
  12. Lundbeck
  13. Eisai
  14. GlaxoSmithKline
  15. Merck
  16. GE Healthcare
  17. Danone Research
  18. Piramal
  19. Novartis
  20. Probiodrug
  21. Biogen
  22. Roche
  23. EIP Pharma

Ask authors/readers for more resources

The term vascular cognitive impairment (VCI) was introduced around the start of the new millennium and refers to the contribution of vascular pathology to any severity of cognitive impairment, ranging from subjective cognitive decline and mild cognitive impairment to dementia. Although vascular pathology is common in elderly individuals with cognitive decline, pure vascular dementia (that is, dementia caused solely by vascular pathology) is uncommon. Indeed, most patients with vascular dementia also have other types of pathology, the most common of which is Alzheimer disease (specifically, the diffuse accumulation of amyloid-beta plaques and neurofibrillary tangles composed of tau). At present, the main treatment for VCI is prevention by treating vascular diseases and other risk factors for VCI, such as hypertension and diabetes mellitus. Despite the current paucity of disease-modifying pharmacological treatments, we foresee that eventually, we might be able to target specific brain diseases to prevent cognitive decline and dementia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available